PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it an excellent choice for therape...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
16 March 2016
|
| In: |
Journal of nuclear medicine
Year: 2016, Jahrgang: 57, Heft: 8, Pages: 1170-1176 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.115.171397 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.2967/jnumed.115.171397 Verlag, kostenfrei, Volltext: http://jnm.snmjournals.org/content/57/8/1170 
|
| Verfasserangaben: | Clemens Kratochwil, Frederik L. Giesel, Melsa Stefanova, Martina Benešová, Marcus Bronzel, Ali Afshar-Oromieh, Walter Mier, Matthias Eder, Klaus Kopka and Uwe Haberkorn |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571447415 | ||
| 003 | DE-627 | ||
| 005 | 20230428184854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180326s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.115.171397 |2 doi | |
| 035 | |a (DE-627)1571447415 | ||
| 035 | |a (DE-576)501447415 | ||
| 035 | |a (DE-599)BSZ501447415 | ||
| 035 | |a (OCoLC)1340995397 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 245 | 1 | 0 | |a PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 |c Clemens Kratochwil, Frederik L. Giesel, Melsa Stefanova, Martina Benešová, Marcus Bronzel, Ali Afshar-Oromieh, Walter Mier, Matthias Eder, Klaus Kopka and Uwe Haberkorn |
| 264 | 1 | |c 16 March 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel ist "177" in 177Lu-labeled hochgestellt | ||
| 500 | |a Gesehen am 26.03.2018 | ||
| 520 | |a Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it an excellent choice for therapeutic application. We retrospectively report our experience with 177Lu-PSMA-617-targeted radionuclide therapy in a case series of mCRPC patients resistant to other treatments. Methods: Patients with PSMA-positive tumor phenotypes were selected by molecular imaging. Thirty patients received 1-3 cycles of 177Lu-PSMA-617. During therapy, pharmacokinetics and radiation dosimetry were evaluated. Blood cell count was checked every 2 wk after the first and every 4 wk after succeeding cycles. Prostate-specific antigen (PSA) was determined every 4 wk. Radiologic restaging was performed after 3 cycles. Results: Twenty-one of 30 patients had a PSA response; in 13 of 30 the PSA decreased more than 50%. After 3 cycles, 8 of 11 patients achieved a sustained PSA response (>50%) for over 24 wk, which also correlated with radiologic response (decreased lesion number and size). Normally, acute hematotoxicity was mild. Diffuse bone marrow involvement was a risk factor for higher grade myelosuppression but could be identified by PSMA imaging in advance. Xerostomia, nausea, and fatigue occurred sporadically (<10%). Clearance of non-tumor-bound tracer was predominantly renal and widely completed by 48 h. Safety dosimetry revealed kidney doses of approximately 0.75 Gy/GBq, red marrow doses of 0.03 Gy/GBq, and salivary gland doses of 1.4 Gy/GBq, irrespective of tumor burden and consistent on subsequent cycles. Mean tumor-absorbed dose ranged from 6 to 22 Gy/GBq during cycle 1. Conclusion: 177Lu-PSMA-617 is a promising new option for therapy of mCRPC and deserves more attention in larger prospective trials. | ||
| 650 | 4 | |a 177Lu | |
| 650 | 4 | |a castration-resistant prostate cancer | |
| 650 | 4 | |a dosimetry | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a PSMA | |
| 650 | 4 | |a radionuclide therapy | |
| 700 | 1 | |a Giesel, Frederik L. |d 1970- |e VerfasserIn |0 (DE-588)129031240 |0 (DE-627)387883878 |0 (DE-576)297457071 |4 aut | |
| 700 | 1 | |a Stefanova, Melsa |e VerfasserIn |0 (DE-588)1135308233 |0 (DE-627)890264562 |0 (DE-576)489759475 |4 aut | |
| 700 | 1 | |a Afshar-Oromieh, Ali |d 1975- |e VerfasserIn |0 (DE-588)130260436 |0 (DE-627)496579711 |0 (DE-576)189580003 |4 aut | |
| 700 | 1 | |a Mier, Walter |d 1966- |e VerfasserIn |0 (DE-588)12029026X |0 (DE-627)69653567X |0 (DE-576)292141599 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine |d New York, NY : Soc., 1964 |g 57(2016), 8, Seite 1170-1176 |h Online-Ressource |w (DE-627)325793603 |w (DE-600)2040222-3 |w (DE-576)09475277X |x 2159-662X |7 nnas |a PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 |
| 773 | 1 | 8 | |g volume:57 |g year:2016 |g number:8 |g pages:1170-1176 |g extent:7 |a PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.115.171397 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://jnm.snmjournals.org/content/57/8/1170 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180326 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 10 |y j | ||
| 998 | |g 12029026X |a Mier, Walter |m 12029026X:Mier, Walter |d 910000 |d 911400 |e 910000PM12029026X |e 911400PM12029026X |k 0/910000/ |k 1/910000/911400/ |p 7 | ||
| 998 | |g 130260436 |a Afshar-Oromieh, Ali |m 130260436:Afshar-Oromieh, Ali |d 910000 |d 911400 |e 910000PA130260436 |e 911400PA130260436 |k 0/910000/ |k 1/910000/911400/ |p 6 | ||
| 998 | |g 1135308233 |a Stefanova, Melsa |m 1135308233:Stefanova, Melsa |d 910000 |d 911400 |e 910000PS1135308233 |e 911400PS1135308233 |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 998 | |g 129031240 |a Giesel, Frederik L. |m 129031240:Giesel, Frederik L. |d 910000 |d 911400 |e 910000PG129031240 |e 911400PG129031240 |k 0/910000/ |k 1/910000/911400/ |p 2 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1571447415 |e 3004335778 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"16 March 2016","dateIssuedKey":"2016"}],"relHost":[{"title":[{"title":"Journal of nuclear medicine","subtitle":"JNM","title_sort":"Journal of nuclear medicine"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2159-662X","1535-5667"],"eki":["325793603"],"zdb":["2040222-3"]},"origin":[{"dateIssuedDisp":"1964-","publisher":"Soc.","publisherPlace":"New York, NY","dateIssuedKey":"1964"}],"name":{"displayForm":["Society of Nuclear Medicine"]},"recId":"325793603","corporate":[{"role":"isb","display":"Society of Nuclear Medicine"}],"disp":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617Journal of nuclear medicine","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"JNM"}],"language":["eng"],"part":{"pages":"1170-1176","extent":"7","issue":"8","text":"57(2016), 8, Seite 1170-1176","volume":"57","year":"2016"},"pubHistory":["Nachgewiesen 5.1964 -"],"note":["Gesehen am 13.12.2021"]}],"physDesc":[{"extent":"7 S."}],"id":{"doi":["10.2967/jnumed.115.171397"],"eki":["1571447415"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617"}],"note":["Im Titel ist \"177\" in 177Lu-labeled hochgestellt","Gesehen am 26.03.2018"],"recId":"1571447415","person":[{"role":"aut","family":"Kratochwil","given":"Clemens","display":"Kratochwil, Clemens"},{"given":"Frederik L.","display":"Giesel, Frederik L.","role":"aut","family":"Giesel"},{"role":"aut","family":"Stefanova","given":"Melsa","display":"Stefanova, Melsa"},{"role":"aut","family":"Afshar-Oromieh","given":"Ali","display":"Afshar-Oromieh, Ali"},{"display":"Mier, Walter","given":"Walter","role":"aut","family":"Mier"},{"display":"Haberkorn, Uwe","given":"Uwe","role":"aut","family":"Haberkorn"}],"name":{"displayForm":["Clemens Kratochwil, Frederik L. Giesel, Melsa Stefanova, Martina Benešová, Marcus Bronzel, Ali Afshar-Oromieh, Walter Mier, Matthias Eder, Klaus Kopka and Uwe Haberkorn"]},"language":["eng"]} | ||
| SRT | |a KRATOCHWILPSMATARGET1620 | ||